After the post-2021 funding contraction, venture capital is re-entering beauty in 2026 — with significantly tighter criteria. The brands attracting capital are vertically integrated, clinically validated, and demonstrably profitable per unit. The 'clean vision' pitch alone no longer closes rounds.